ArticleThe pharmacogenomics journal2025
Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort.
Article in The pharmacogenomics journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined the association of selected candidate pharmacodynamic (PD) genes in MDD with treatment outcomes, defined according to remission thresholds for Hamilton Depression Rating Scale (HDRS) with 6- and 17- items. To this end, we recruited 158 individuals living with MDD followed in an academic community mental health center. We reconstructed their clinical history and tested the association of a selected panel of pharmacodynamic genes with clinical remission. Our multivariate models were corrected for illness duration, substance use, lifetime stressful events, and sex. We found partially concordant associations for candidate biomarkers and clinical remission defined with HDRS-6 and HDRS-17. In the logistic regression model, two polymorphisms were statistically significantly associated with HDRS-17 remission: namely rs10975641 and rs11628713. Our results suggest that polymorphisms in PD genes might influence clinical response in MDD. Interestingly, we showed some degree of concordance of the association depending on the definition of the response.
Indexed as
Identifiers
40263270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.